11 May 2021

SparingVision to Present at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting

Sparingvision - Ysios Capital

Paris, May 06, 2021SparingVision (or the ‘Company’), a genomic medicine company developing vision saving treatments for ocular diseases, is pleased to announce that it has presented three posters highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06, at the Association for Research in Vision and Ophthalmology (‘ARVO’) 2021 Annual Meeting. Details of the posters can be found below.

Poster: SPVN06, a Novel Mutation-Independent AAV-based Gene Therapy, Protects Cone Degeneration in a Pig Model of Retinitis Pigmentosa (‘RP’) (Abstract #3543982) SparingVision administered SPVN06 via subretinal injection in pigs in their first postnatal week and evaluated its effects on cone morphology, Dr Jennifer Noel, from the University of Louisville presented the poster on May 3 2021 from 11:15 AM to 1:00 PM EDT. The administration of the AAV SPVN06 therapy was found to preserve cone morphology as well as preserve m-opsin expression in cone segments. It also leads to a greater expression of rod-derived cone viability factor (‘RdCVFL’).

Poster: Correlations between progression markers in rod-cone dystrophy due to mutations in RHO, PDE6A, or PDE6B (Abstract #3545695) Dr. Daniel Chung, Chief Medical Officer of SparingVision presented first results from the Phenorod1 retrospective natural history on May 3 2021 between 4:30 PM to 6:15 PM EDT. Strong correlations between structural and functional parameters of retinitis pigmentosa were observed and these results could help to define new composite markers for the evaluation of the disease severity; they could also be of interest when evaluating the efficacy of new therapies for treating patients with a slow progression of the disease.

Poster: A 1-Month Toxicology and Biodistribution NHP Pilot Study Evaluating a Single Subretinal Bilateral Administration of SPVN06 – A Novel AAV-Based Gene Therapy for the Treatment of Rod-Cone Dystrophies Agnostic of the Causative Mutation (Abstract #3531256)

  • Dr. Melanie Marie, Principal Scientist at SparingVision presented the results from the Company’s 1-month safety study of SPVN06 in NHP on May 5, 2021 from 2:45 PM to 4:30 PM EDT. Four primates received a subretinal injection of SPVN06 and the following parameters were evaluated: clinical observations, body weights, clinical pathology, organ weights and macroscopic observations. SPVN06 was found to be well tolerated and there were no systemic effects on any of the parameters assessed.


About SparingVision:

SparingVision is a genomic medicines company, translating pioneering science into vision saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is SPVN06, a gene independent treatment for retinitis pigmentosa (RP), the most common inherited retinal disease affecting two million people worldwide. SPVN06 could form the basis of a suite of new sight saving treatments as it could be applicable to many other retinal diseases, regardless of genetic cause.

The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.

About SPVN06:

SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy approach comprised of one neurotrophic factor and one enzyme reducing oxidative stress which, acting synergistically, aim at slowing or stopping the degeneration of cone photoreceptors, which inevitably leads to blindness in patients with rod-cone dystrophies (RCD). SparingVision’s primary disease target is Retinitis Pigmentosa (RP), one of the most common inherited retinal diseases that affects two million patients worldwide. There is currently no treatment approved to treat RP patients independently of their genetic background. This approach is potentially applicable to many more diseases where the loss of rods is known to be an early signal of the disease. First-in-man trials, with SPVN06 in patients with RP, will be commencing in H2 2021.


Stéphane Boissel President and CEO
Nathalie Trepo
Investor Relations

Consilium Strategic Communications
Amber Fennell, Olivia Manser, Davide Salvi, Priit Piip+44 (0)20 3709 5700